TESEO Trial Shortens Chagas Disease Treatment
Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 23, 2026
The results could improve treatment adherence and expand access to Chagas disease therapy, potentially benefiting manufacturers of benznidazole and public health programs in endemic regions. However, the impact on major pharmaceutical markets is limited because Chagas is a neglected tropical disease with a small commercial footprint and phase 3 confirmation is still required.
The TESEO trial, a phase 2b randomized clinical study co-led by the Barcelona Institute for Global Health (ISGlobal), the University of Texas at Austin (UTEP) and the Bolivian organization CEADES, found that a 30-day once-daily course of benznidazole is as effective as the current 60-day twice-daily standard for treating chronic Trypanosoma cruzi infection, the parasite that causes Chagas disease. Results were published in The Lancet on September 22, 2026. The trial enrolled 450 adults at three centers in Bolivia and compared six regimens: three benznidazole schedules (60-day standard, 30-day and 90-day) and three nifurtimox schedules. Only the 30-day benznidazole regimen significantly reduced side effects, with 37 percent of participants experiencing a drug-related adverse event versus 60 percent on the standard regimen, and 83 percent completing treatment without interruption versus 60 percent. Three years after treatment, the parasite remained undetectable in 94 percent of the 30-day group versus 95 percent in the standard group, meeting the prespecified non-inferiority criterion. The shorter course also uses a quarter of the drug, allowing four patients to be treated with the amount previously used for one. Nifurtimox regimens were less effective overall, with clearance rates of 81 to 90 percent. The trial was funded by the Norway — Norwegian Institute of Public Health, part of the United States — National Institutes of Health, with partial support from the United States — National Institute on Minority Health and Health Disparities and UTEP's Border Biomedical Research Center. Larger phase 3 trials are needed before the 30-day regimen can be incorporated into treatment guidelines. Chagas disease affects more than seven million people worldwide, mainly in Latin America, and is a growing public health concern in the United States, Europe and Japan.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard